Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multi-center, pilot study of Nivolumab in pediatric
patients with recurrent or refractory hypermutant malignancies aged 12 months to 18 years of
age. This study is to assess clinical and radiological benefits of treatment with Nivolumab
in children with hypermutated cancers, including those with bMMRD syndrome. It is our
expectation that patients with bMMRD syndrome will account for the majority of patients
enrolled on this study.